Arndt Vogel on the NALIRICC trial of nanoliposomal irinotecan in pretreated advanced biliary tract cancer

Arndt Vogel (Toronto General Hospital) discusses the NALIRICC trial of nanoliposomal irinotecan added to fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies. Read the full article: https://www.thelancet.com/journals/langas/article/PIIS2468-1253(24)00119-5?dgcid=buzzsprout_icw_podcast_generic_langas Continue this conversation on social! Follow us today at... https://twitter.com/thelancet https://instagr...

Om Podcasten

Hugh Thomas, Deputy Editor at The Lancet Gastroenterology & Hepatology, in conversation with the journal’s authors, explores their latest research and its impact on people’s health, healthcare, and health policy.A monthly audio companion to the journal, this podcast covers a broad range of topics, from predicting clinical outcomes in NAFLD to immunosuppressant withdrawal in patients with Crohn’s disease, the primary antibiotic resistance of Helicobacter pylori to surgical versus non-surgical management of malignant bowel obstruction, and more.